Stockreport

Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Kineta, Inc.  (KA) 
PDF Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research [Read more]